Skip to content

Can-Fite BioPharma Ltd.: 20-F filed 2021-03-25

What Can-Fite BioPharma Ltd. reported in its annual report (foreign private issuer) filed 2021-03-25 (fiscal FY 2020): 29 published measures, 73 facts as tagged in accession 0001213900-21-017630.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2021-03-25
Fiscal period
fiscal FY 2020
Accession
0001213900-21-017630 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Can-Fite BioPharma Ltd. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-12-319,523,000USD
At 2019-12-318,174,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-12-316,074,000USD
At 2019-12-312,442,000USD
At 2018-12-313,015,000USD
At 2017-12-312,984,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-12-318,268,000USD
At 2019-12-312,697,000USD
At 2018-12-313,615,000USD
At 2017-12-313,505,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-14,443,000USD366
2019-01-01 to 2019-12-31-12,625,000USD365
2018-01-01 to 2018-12-31-6,571,000USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-12,063,000USD366
2019-01-01 to 2019-12-31-11,084,000USD365
2018-01-01 to 2018-12-31-4,155,000USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-12-3126,000USD366
2019-01-01 to 2019-12-313,000USD365
2018-01-01 to 2018-12-3133,000USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-01-01 to 2020-12-31763,000USD366
2019-01-01 to 2019-12-312,032,000USD365
2018-01-01 to 2018-12-313,820,000USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-12-3117,683,000USD366
2019-01-01 to 2019-12-3110,167,000USD365
2018-01-01 to 2018-12-314,387,000USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-26,000USD366
2019-01-01 to 2019-12-31-3,000USD365
2018-01-01 to 2018-12-31-33,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-12-31-125,469,000USD
At 2019-12-31-110,311,000USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-12-3150,000USD
At 2019-12-3136,000USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-14,139,000USD366
2019-01-01 to 2019-12-31-12,007,000USD365
2018-01-01 to 2018-12-31-5,414,000USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-12-319,400,000USD
At 2019-12-317,144,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-12-311,269,000USD
At 2019-12-313,271,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-01-01 to 2020-12-3111,951,000USD366
2019-01-01 to 2019-12-3110,976,000USD365
2018-01-01 to 2018-12-316,075,000USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-12-31463,769,463shares
At 2019-12-31120,652,683shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-12-3197,380,000USD
At 2019-12-31103,401,000USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-12-311,127,000USD
At 2019-12-311,127,000USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-12-3173,000USD
At 2019-12-3182,000USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-12-3167,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-12-31270,000USD
At 2019-12-31244,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-12-31220,000USD
At 2019-12-31208,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-12-311,057,000USD
At 2019-12-314,383,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-14,443,000USD366
2019-01-01 to 2019-12-31-12,625,000USD365
2018-01-01 to 2018-12-31-6,567,000USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-12-312,951,000USD366
2019-01-01 to 2019-12-313,063,000USD365
2018-01-01 to 2018-12-313,159,000USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-12-3112,000USD366
2019-01-01 to 2019-12-3114,000USD365
2018-01-01 to 2018-12-3114,000USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-304,000USD366
2019-01-01 to 2019-12-31-618,000USD365
2018-01-01 to 2018-12-31-1,153,000USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-12-3123,000USD366
2019-01-01 to 2019-12-3129,000USD365
2018-01-01 to 2018-12-3118,000USD365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2018-01-01 to 2018-12-314,000USD365

Inspect the source

Entity
Can-Fite BioPharma Ltd. / CIK 0001536196
Captured
2026-09-20T09:17:01.019Z
SEC response SHA-256
6b71e874ffdef15c19b99ed81e159a170e416c2d6e6f6f9c176c37a11b34034c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001536196.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))